SPONTANEOUS GRAM-NEGATIVE BACTERIAL MENINGITIS INHOSPITAL FOR TROPICAL DISEASES

Dang Trung Nghia Ho, Thi Hong Hanh Bui, Thi Han Ny Nguyen, Trong Duc Du, Phu Huong Lan Nguyen, Van Tan Le, Nguyen Huy Man Dinh, Thi Hue Tai Luong, Duc Vinh Le, Van Vinh Chau Nguyen

Main Article Content

Abstract

Background: In the past decade, there was an emergence of spontaneous Gram-negative bacilli bacterial meningitis (SGNBM), leading to negative impact on prognosis and mortality. Aging and/or underlying conditions were at increased risk for this illness.


Methods: A case series study of SGNBM was conducted at the Hospital for Tropical Diseases, in Ho Chi Minh City, Vietnamfrom 2014 to 2020.


Results: A total of 68 patients were recruited in our study from January 2014 to June 2020. Typical characteristics of patients were male sex (72.1%), middleage and farmer (54.4%). The most common underlying condition was diabetes mellitus (41.2%). Notably, long-term corticosteroid andco-infection with Strongyloides stercoralis were also common in these patientswith 21/68 (30.9%) and 20/56 (35.7%) cases, respectively. Among patients whose CSF were tested with real-time PCR Strongyloides stercoralis, we found parasite’s existence in 3 cases. Escherichia coli and Klebsiella pneumoniae were the most causative pathogens of SGNBM, accounting for 42.5% (29/68) and 32,3% (22/68) of all cases, respectively. Furthermore, ESBL-producing E. Colis trains accounted for 75.9% (22/29) of all E. Coli meningitis cases. Hence, Ceftriaxone, which is the first-choice antibiotic in community-acquired meningitis,was inappropriate for 35.6% (16/45)patients. Septic shock was presented in 32.3% (21/65) cases with poor outcomes. The overall mortality and morbidity rate from SGNBM were 35.4% and 20%, respectively.


Conclusions: SGNBM is a severe disease resulting to a high rate of mortality and morbidity. Diabetes, taking long-term corticosteroid treatment and strongyloidiasis could be the risks for this condition. It was necessary to use Carbapenem as the empiric antibiotic to cover the ESBL-producing pathogens.

Article Details